| HLOŽKOVÁ, Michaela, Jana FIGULOVÁ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Nikola TOM, Yvona BRYCHTOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients. In Haematologica (2016); 101(s1): 417 (21st Congress of the EHA). 2016. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1363946,
author = {Hložková, Michaela and Figulová, Jana and Navrkalová, Veronika and Malčíková, Jitka and Šmardová, Jana and Tom, Nikola and Brychtová, Yvona and Doubek, Michael and Mayer, Jiří and Pospíšilová, Šárka and Trbušek, Martin},
booktitle = {Haematologica (2016); 101(s1): 417 (21st Congress of the EHA)},
title = {Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients.},
year = {2016}
}
TY - CONF
ID - 1363946
AU - Hložková, Michaela - Figulová, Jana - Navrkalová, Veronika - Malčíková, Jitka - Šmardová, Jana - Tom, Nikola - Brychtová, Yvona - Doubek, Michael - Mayer, Jiří - Pospíšilová, Šárka - Trbušek, Martin
PY - 2016
TI - Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients.
ER -
HLOŽKOVÁ, Michaela, Jana FIGULOVÁ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Nikola TOM, Yvona BRYCHTOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients. In \textit{Haematologica (2016); 101(s1): 417 (21st Congress of the EHA)}. 2016.
|
